Genitourinary Cancers
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localised prostate cancer.
Read More at ClinicalTrials.gov
Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer.
Read More at ClinicalTrials.gov
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Read More at ClinicalTrials.gov
Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Read More at ClinicalTrials.gov
Investigators:
Jonathan Chen, MD, PhD
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer: A Prospective Registry Trial
Read More at ClinicalTrials.gov
Investigators:
Jay Liao, MD
Head and Neck Cancers
RAMPART: A Phase II, Multicenter, Single-Arm Clinical Trial of Definitive Radiotherapy and CeMiPlimAb-Rwlc ImmunoTherapy for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma
Read More at ClinicalTrials.gov
Investigators:
Upendra Parvathaneni, MB, FRANCR
Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100Mg/M2 ) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (30Mg/M2) For Patients With Locoregionally Advanced Squamous Cell Carcinoma Of the Head and Neck (SCCHN)
Read More at ClinicalTrials.gov
Randomized Phase II/III Trial Of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, Or Cisplatin-Atezolizumab In Pathologic High-Risk Squamous Cell Cancer Of The Head And Neck
Read More at ClinicalTrials.gov
A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of TEMPOL for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy
Read More at ClinicalTrials.gov
Investigators:
Jay Liao, MD
Other
A Phase I Study Assessing the Safety and Tolerability of Ascending Doses of AZD1390 in Combination with Stereotactic Body Radiation Therapy (SBRT) in Patients with Metastatic Solid Tumor Malignancies
Read More at ClinicalTrials.gov
Investigators:
Jonathan Yang, MD, PhD
Kazia: A Phase I Study with Expansion Cohort of Concurrent GDC-0084 with Radiation Therapy for Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations
Read More at ClinicalTrials.gov
Investigators:
Jonathan Yang, MD, PhD
Increasing Native Radiation Oncology Access: Disparities and Solutions (INROADS) – Provider Survey / INROADS – Patient Survey
Read More at ClinicalTrials.gov
Investigators:
Lia Halasz, MD
Radiation Oncology Peripheral Blood Banking Protocol to Examine Immunologic Changes After Radiation Therapy
Read More at ClinicalTrials.gov
Investigators:
Jing Zeng, MD
Biodosimetry: Quantitation of radiation induced protein adducts using mass spectrometry
Read More at ClinicalTrials.gov
Investigators:
Peter Goff, MD, PhD
Pediatric proton consortium registry (PPCR): A MultiCenter Registry of Pediatric Patients Treated with Proton Radiation Therapy
Read More at ClinicalTrials.gov
Investigators:
Ralph Ermoian, MD
Evaluation Tracking Project: A Prospective Chart Review of Patients Treated with Radiation Therapy
Read More at ClinicalTrials.gov
Investigators:
Jing Zeng, MD